A detailed history of Intellectus Partners, LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Intellectus Partners, LLC holds 29,992 shares of BMY stock, worth $1.73 Million. This represents 0.41% of its overall portfolio holdings.

Number of Shares
29,992
Previous 31,335 4.29%
Holding current value
$1.73 Million
Previous $1.3 Million 19.29%
% of portfolio
0.41%
Previous 0.36%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 06, 2024

SELL
$39.66 - $51.75 $53,263 - $69,500
-1,343 Reduced 4.29%
29,992 $1.55 Million
Q2 2024

Jul 18, 2024

SELL
$40.25 - $52.99 $251,683 - $331,346
-6,253 Reduced 16.64%
31,335 $1.3 Million
Q1 2024

May 03, 2024

SELL
$47.98 - $54.4 $6,621 - $7,507
-138 Reduced 0.37%
37,588 $2.04 Million
Q4 2023

Feb 05, 2024

BUY
$48.48 - $57.85 $27,827 - $33,205
574 Added 1.55%
37,726 $1.94 Million
Q3 2023

Oct 25, 2023

SELL
$57.89 - $64.73 $54,127 - $60,522
-935 Reduced 2.45%
37,152 $2.16 Million
Q2 2023

Jul 31, 2023

SELL
$63.71 - $70.74 $43,259 - $48,032
-679 Reduced 1.75%
38,087 $2.44 Million
Q1 2023

May 04, 2023

SELL
$65.71 - $74.53 $11,827 - $13,415
-180 Reduced 0.46%
38,766 $2.69 Million
Q4 2022

Feb 02, 2023

SELL
$68.48 - $81.09 $15,271 - $18,083
-223 Reduced 0.57%
38,946 $2.8 Million
Q3 2022

Nov 14, 2022

BUY
$0.13 - $76.84 $528 - $312,124
4,062 Added 11.57%
39,169 $2.79 Million
Q2 2022

Aug 12, 2022

SELL
$72.62 - $79.98 $76,614 - $84,378
-1,055 Reduced 2.92%
35,107 $2.72 Million
Q1 2022

May 16, 2022

BUY
$61.48 - $73.72 $291,968 - $350,096
4,749 Added 15.12%
36,162 $2.66 Million
Q4 2021

Feb 14, 2022

SELL
$53.63 - $62.52 $59,690 - $69,584
-1,113 Reduced 3.42%
31,413 $1.96 Million
Q3 2021

Nov 16, 2021

SELL
$59.17 - $69.31 $52,483 - $61,477
-887 Reduced 2.65%
32,526 $1.94 Million
Q2 2021

Aug 13, 2021

BUY
$61.91 - $67.42 $109,766 - $119,535
1,773 Added 5.6%
33,413 $2.23 Million
Q1 2021

May 17, 2021

BUY
$59.34 - $66.74 $44,148 - $49,654
744 Added 2.41%
31,640 $2.01 Million
Q4 2020

Feb 18, 2021

BUY
$57.74 - $65.43 $1.55 Million - $1.76 Million
26,896 Added 672.4%
30,896 $1.93 Million
Q4 2020

Feb 12, 2021

SELL
$57.74 - $65.43 $1.55 Million - $1.75 Million
-26,815 Reduced 87.02%
4,000 $1.93 Million
Q3 2020

Nov 16, 2020

BUY
$57.43 - $63.64 $208,930 - $231,522
3,638 Added 13.39%
30,815 $1.86 Million
Q2 2020

Aug 14, 2020

SELL
$54.82 - $64.09 $176,958 - $206,882
-3,228 Reduced 10.62%
27,177 $1.6 Million
Q1 2020

May 14, 2020

SELL
$46.4 - $67.43 $114,747 - $166,754
-2,473 Reduced 7.52%
30,405 $1.7 Million
Q4 2019

Jan 24, 2020

BUY
$49.21 - $64.19 $978,196 - $1.28 Million
19,878 Added 152.91%
32,878 $2.11 Million
Q3 2019

Oct 11, 2019

BUY
$42.77 - $50.71 $21,598 - $25,608
505 Added 4.04%
13,000 $659,000
Q2 2019

Aug 08, 2019

BUY
$44.62 - $49.34 $530,219 - $586,307
11,883 Added 1941.67%
12,495 $567,000
Q4 2018

Feb 14, 2019

SELL
$48.76 - $63.23 $164,955 - $213,907
-3,383 Reduced 84.68%
612 $32,000
Q3 2018

Nov 15, 2018

BUY
$55.19 - $62.25 $6,181 - $6,972
112 Added 2.88%
3,995 $248,000
Q4 2017

Feb 13, 2018

SELL
$59.94 - $65.35 $4,795 - $5,228
-80 Reduced 2.02%
3,883 $238,000
Q2 2017

Aug 15, 2017

BUY
N/A
3,963
3,963 $221,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $123B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Intellectus Partners, LLC Portfolio

Follow Intellectus Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Intellectus Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Intellectus Partners, LLC with notifications on news.